Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 1.00 |
| ▸ | FABP5 | Q01469 | 3/20 | 1.00 |
| ▸ | FABP3 | P05413 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573159 | 1.00 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL12951764 | 0.95 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL6419189 | 0.93 | FABP4 (0.97) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL29114062 | 0.93 | FABP4 (0.97) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL31156410 | 0.93 | FABP4 (0.97) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL6833930 | 0.93 | FABP4 (0.97) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL30549325 | 0.89 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL150033 | 0.89 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL27763456 | 0.87 | FABP4 (0.96) | FABP4FABP5FABP3KDM4EHDAC6 | |
| SCHEMBL1150189 | 0.87 | FABP4 (0.75) | FABP4FABP5FABP3KDM4EHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226398-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2025-02-18 | — | — | US | claimed |
| US-20220096435-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2022-03-31 | — | — | US | claimed |
| EP-3755322-A1 | TARGETING LIPID METABOLISM AND FREE FATTY ACID (FFA) OXIDATION TO TREAT DISEASES MEDIATED BY RESIDENT MEMORY T CELLS (TRM) | The Brigham & Women's Hospital, Inc. (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200375965-A1 | Targeting Lipid Metabolism and Free Fatty Acid (FFA) Oxidation to Treat Diseases Mediated by Resident Memory T Cells (TRM) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-03 | — | — | US | claimed |
| EP-3532049-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | Ticure Ltd. (IL) | 2019-09-04 | — | — | EP | claimed |
| WO-2019161294-A1 | TARGETING LIPID METABOLISM AND FREE FATTY ACID (FFA) OXIDATION TO TREAT DISEASES MEDIATED BY RESIDENT MEMORY T CELLS (TRM) | KUPPER THOMAS S (US) | 2019-08-22 | — | — | WO | claimed |
| WO-2019043279-A1 | COMPOSITIONS ABLE TO MODULATE THE STIMULATION OF ENDOGENOUS GDNF FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SERVICIO ANDALUZ DE SALUD (ES) | 2019-03-07 | — | — | WO | claimed |
| WO-2018078624-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2018-05-03 | — | — | WO | claimed |
| US-20140363522-A1 | Compositions and Methods for Treating and/or Preventing Cancer by Inhibiting Fatty Acid Binding Proteins | NIH - DEITR | 2014-12-11 | — | — | US | claimed |
| US-8748470-B2 | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins | THE UNIVERSITY OF CHICAGO (US) | 2014-06-10 | — | — | US | claimed |
| US-20120289570-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS | NIH | 2012-11-15 | — | — | US | claimed |
| US-20260132106-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | CELLORAM, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4719369-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12570603-B2 | FABP4/5 inhibitors, methods of use and methods of making | CELLORAM INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025226670-A1 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | CELLORAM, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570603-B2 | FABP4/5 inhibitors, methods of use and methods of making | FABP5, FABP1, FABP4 | FABP4 3/4885FABP5 1/4885FABP3 5/4885 |
| US-20260132106-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP4, FABP1 | FABP4 2/4885FABP5 1/4885FABP3 5/4885 |
| US-20220096435-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | FABP4 1/4885FABP5 4/4885FABP3 5/4885 |
| US-12226398-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | FABP4 1/4885FABP5 4/4885FABP3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.